Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. - Test2 - elhamkhani - TriplyDB

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

http://www.wikidata.org/entity/Q34219342

about

Treatment for small cell lung cancer, where are we now?-a review Medical management of lung cancer: Experience in China Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer.Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604 Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Molecular understanding of lung cancers-A review.Small cell lung cancer: therapies and targets The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.Case report of a patient with left ventricular assistance device undergoing chemotherapy for a new diagnosis of lung cancer Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.The downregulation of Bcl-xL/Bcl-2-associated death promoter indicates worse outcomes in patients with small cell lung carcinoma.Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer.Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.MiR-182-5p protects inner ear hair cells from cisplatin-induced apoptosis by inhibiting FOXO3a Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.Medical treatment of small cell lung cancer: state of the art and new development.SEOM clinical guidelines for the treatment of small-cell lung cancer 2013.Chemotherapy advances in small-cell lung cancer Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.Advances in pharmacotherapy of small cell lung cancer.Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.Smoking, inflammation and small cell lung cancer: recent developments.Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Optimal drugs for second-line treatment of patients with small-cell lung cancer.Unravelling the biology of SCLC: implications for therapy.Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.

P2860

Q26767023-AA7D822A-948A-4089-8BDA-CD2930579F82 Q26798257-47B44FFB-348E-42E6-93C8-B01848076550 Q30238552-9AAF3FAB-8121-4D66-B08F-C7E15F775663 Q33416668-C6792B14-FAC3-41AE-BD1B-A18C10ED3EC0 Q33442158-B93B9EAE-F498-4B9B-8ACD-E190285A4A85 Q33443519-DE75B4ED-E64A-4275-85F7-5E8D2BF6EB86 Q33628898-7F3C2FCE-E366-415C-AF1D-05B8C9C884DE Q34250859-1E3BC8B7-396D-4BAC-B3BB-3AFA6A826948 Q34334418-9669CBDB-2CB7-4331-A122-ADF7253637F4 Q34365873-06FB7CF7-0329-478F-A623-5B2E03F6ABB2 Q34653709-4281DAE1-9CD0-4EBD-8CF0-E229B8DE12C1 Q34653756-24EA880B-99DA-4BAA-8B3A-809FC0450D74 Q35212727-42AC7825-5347-4A08-AFD1-90DFDFEA9BDB Q35271257-433A4A5F-A430-4EBF-9868-03CC512DD9C9 Q35650181-16BB1FFC-2DAD-4650-AE61-F4D360CCFD2E Q36030323-BED2818F-2D76-47E8-9ED7-7C422D2ADD5F Q36184617-F601AD63-D8C4-4F21-9126-F30C76CA62DC Q36375317-A37F5C4F-4294-4873-80FE-5AB942D7FC74 Q36594253-884876FD-C594-4BB6-8383-ECBD37E6A8AB Q36776647-9395AD14-0039-4666-856B-7E12187CE9B7 Q36833865-97E64E61-518D-4A24-AEA6-8F792FDC89F7 Q36948373-088D84C0-7622-4E34-8FAF-E8FBF639C93B Q37053564-BF0E39A4-9C8A-45EF-B0A4-75ECF0A1923F Q37117864-37E1EA42-6F4C-4150-87E0-295061D88E79 Q37330806-DBD45EE3-D4F6-438C-A8EF-401DED7725E2 Q37624426-61B9DC0F-046B-406E-A07D-ACC6757CA47A Q37631597-2F56C6FD-07A4-4491-B6E1-8615D4CB8C3E Q38125489-94AC35C8-31A3-4192-B2E9-3426A3623809 Q38134304-45A82072-E72B-440D-8AE3-E56F541F97DD Q38155856-D9580F7F-319B-4C7E-A3B1-B590E5EC14D3 Q38183430-7612D92B-A9AF-4993-89DD-8324BF869E83 Q38254295-F39C4FDA-E075-4DC4-80B3-0CCDF7070627 Q38325864-82D553E0-4B0D-4510-A84B-A69958F3E455 Q38569752-9408958D-3213-4A88-B41B-1F2824AB36D3 Q38637751-269011FD-5523-4CCE-A2F7-E2BA5931609A Q38677762-B6C21C4A-1D5D-4AE6-9C55-DD1E89986651 Q38734204-916B82B6-1AD3-4C8E-ABC9-D7294DF0683B Q38769421-4F66CFF7-AB8F-483D-A317-F263F744B411 Q38965866-06C72D88-6E45-448F-AEC6-F40E3780939D Q39107722-38F044BE-1A5D-4E66-9B05-4799B58C05D3

P2860

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

http://www.wikidata.org/entity/Q34219342

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Carboplatin- or cisplatin-base ...... is of individual patient data.

@ast

Carboplatin- or cisplatin-base ...... is of individual patient data.

@en

Carboplatin- or cisplatin-base ...... is of individual patient data.

@nl

type

label

Carboplatin- or cisplatin-base ...... is of individual patient data.

@ast

Carboplatin- or cisplatin-base ...... is of individual patient data.

@en

Carboplatin- or cisplatin-base ...... is of individual patient data.

@nl

prefLabel

Carboplatin- or cisplatin-base ...... is of individual patient data.

@ast

Carboplatin- or cisplatin-base ...... is of individual patient data.

@en

Carboplatin- or cisplatin-base ...... is of individual patient data.

@nl

P1433

Q34219342-2D8A8B6D-0309-441D-85C8-602F873AC7E1

P1476

Q34219342-6E4945BA-7946-45D9-81EE-B0F09ABA5DAF

P2093

Q34219342-0D7854A6-631A-4BB5-8743-27C1FFFFB439

Q34219342-48053B4F-64A8-4E5F-9FF3-0A387B76C726

Q34219342-4F934144-8735-415A-8E25-5CE1E9C4BE86

Q34219342-73DF985A-BBFB-42FB-9872-42DA859705DE

Q34219342-7773F9CC-D649-4E7E-BBB4-9C2E3063BC8D

Q34219342-85629C41-97EA-4331-A756-8005C48F0DC2

Q34219342-8CF6BA6A-A075-44DE-A124-31737EA50319

Q34219342-AA80BD8E-0CB7-4514-A176-9CB49A41E396

Q34219342-E1C41A07-4C51-4F72-978F-F07D30C8204A

Q34219342-FCA8F92A-62F9-4DC4-A3D1-D0DE20462800

P304

Q34219342-2E0E1386-769A-4546-8455-EE2B26BEB2F5

P31

Q34219342-CCD55E58-4FDE-48F0-9A67-B36173AA2258

Q34219342-ecea4f9c-7649-4bd2-a2bc-20a096136719

P356

Q34219342-8A810EF7-D9ED-48F8-B5CD-887F300AF96C

P407

Q34219342-E16B2C5E-2B21-4DA0-8123-415EB2F9A8C6

P433

Q34219342-C9B99704-2C70-4AD7-97DC-FA03542E4FFD

P478

Q34219342-20213216-F84C-48EE-8D1E-A679F26E36B4

P50

Q34219342-0252D31A-1FC9-431C-BB0F-07BC353FFA46

Q34219342-3BC4E7B2-017F-491C-9A07-24A9BC24E277

Q34219342-54FD7BC9-F1C4-4343-A9C7-8D44772D4B71

Q34219342-B5A1F61F-6953-4D49-BC7B-A13291945E8C

Q34219342-C68C17AD-6D71-4471-8D0C-F7558A2C6ABC

Q34219342-F19F0735-B807-4780-BB51-09D6EFDE77E7

P577

Q34219342-6F73BCF4-4BCF-4E93-BBCC-937145CECC4E

P5875

Q34219342-EA56124C-6710-4080-B114-535AA38B46F8

P698

Q34219342-8908BCAB-FB30-438B-A67B-90871D764D6D

P921

Q34219342-6A31C38D-5CC5-497B-943F-315F410A290F

Q34219342-76458509-D0FD-430D-8E5D-9098B9DE3FB8

Q34219342-96C67D27-0078-41D3-BCD9-4D9E7CC1A0C8

P356

JCO.2011.40.4905

P1433

Journal of Clinical Oncology

P1476

Carboplatin- or cisplatin-base ...... is of individual patient data.

@en

P2093

Dimosthenis Vasilios Skarlos

http://www.w3.org/2001/XMLSchema#string

Epaminondas Samantas

http://www.w3.org/2001/XMLSchema#string

Francesco Perrone

http://www.w3.org/2001/XMLSchema#string

Hiroaki Okamoto

http://www.w3.org/2001/XMLSchema#string

Martin Früh

http://www.w3.org/2001/XMLSchema#string

Olga Martelli

http://www.w3.org/2001/XMLSchema#string

Robin Michael Rudd

http://www.w3.org/2001/XMLSchema#string

Taro Shibata

http://www.w3.org/2001/XMLSchema#string

Tomohide Tamura

http://www.w3.org/2001/XMLSchema#string

Wendi Qian

http://www.w3.org/2001/XMLSchema#string

P304

1692-1698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.40.4905

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Di Maio

Cesare Gridelli

P577

2012-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223985671

http://www.w3.org/2001/XMLSchema#string

P698

22473169

http://www.w3.org/2001/XMLSchema#string

P921